Product Inquiry
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| KN-057 | KN-057; KN057 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Hemophilia A; Hemophilia B | Details |
| MG-1113 | MG-1113 | Phase 1 Clinical | GC Biopharma Corp | Hemophilia A | Details |
| AP-017 | AP017; AP-017 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hemophilia A; Hemophilia B | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Concizumab | mAbTFPI2021; NN-7415; NNC-0172-0000-2021; Anti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021 | Approved | Novo Nordisk A/S | Alhemo | Canada | Hemophilia B | Novo Nordisk Canada Inc | 2023-04-17 | Hemophilia A; Hemophilia B; Hemorrhage | Details |
| Marstacimab | PF-6741086; PF-06741086 | Approved | Pfizer Inc | HYMPAVZI | United States | Hemophilia A; Hemophilia B | Pfizer Inc | 2024-10-11 | Hemophilia A; Hemophilia B; Hemorrhage | Details |